DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

The compound database

Peptide Databasepage 3

264 therapeutic peptides with research summaries, clinical findings, and regulatory status. Every claim is cited.

FDA-approved
90
FDA-approved
Awaiting FDA
8
Awaiting FDA
No lawful pathway
166
No lawful pathway
73–108 of 264
  1. 073

    Octreotide (Sandostatin)

    A synthetic eight-amino acid analog of somatostatin with a much longer duration of action than native somatostatin, whose very short half-life requires…

    Gastrointestinal · FDA Approved · Subcutaneous injection, Intramuscular injection (LAR), Intravenous

    FDA-approved
  2. 074

    Lanreotide (Somatuline Depot)

    A synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and lower affinity for SSTR5. The long-acting formulation (Autogel, sold in the US…

    Gastrointestinal · FDA Approved · Deep subcutaneous injection (monthly)

    FDA-approved
  3. 075

    Pasireotide (Signifor)

    A multireceptor-targeted somatostatin analog with affinity for SSTR1, SSTR2, SSTR3 and SSTR5, including high affinity for SSTR5. Corticotroph adenomas in…

    Gastrointestinal · FDA Approved · Subcutaneous injection (twice daily), Intramuscular injection (monthly LAR)

    FDA-approved
  4. 076

    Plecanatide (Trulance)

    A synthetic 16-amino acid analog of uroguanylin, an endogenous intestinal peptide that regulates fluid and electrolyte balance in the GI tract. Plecanatide…

    Gastrointestinal · FDA Approved · Oral

    FDA-approved
  5. 077

    Linaclotide (Linzess)

    A synthetic 14-amino acid peptide structurally related to the heat-stable enterotoxin of Escherichia coli and the endogenous peptide guanylin. Linaclotide is a…

    Gastrointestinal · FDA Approved · Oral

    FDA-approved
  6. 078

    Secretin

    A 27-amino acid peptide hormone produced by S-cells of the duodenal and jejunal mucosa in response to acid entering the small intestine. Secretin stimulates…

    Gastrointestinal · FDA Approved · Intravenous

    FDA-approved
  7. 079

    Larazotide

    A synthetic octapeptide tight junction regulator derived from a Vibrio cholerae toxin, described as a zonulin antagonist. In laboratory studies larazotide…

    Gastrointestinal · Investigational · Oral

    No lawful pathway
  8. 080

    Ziconotide (Prialt)

    A synthetic 25-amino acid peptide identical to omega-conotoxin MVIIA from the venom of the marine cone snail Conus magus. Ziconotide potently and selectively…

    Pain · FDA Approved · Intrathecal infusion

    FDA-approved
  9. 081

    Difelikefalin (Korsuva)

    A peripherally restricted, selective kappa-opioid receptor (KOR) agonist peptide developed to reduce itch. Its limited central nervous system penetration is…

    Pain · FDA Approved · Intravenous (post-dialysis)

    FDA-approved
  10. 082

    ARA-290

    A synthetic 11-amino acid peptide (also called cibinetide or pyroglutamate helix B surface peptide) modeled on the helix B region of erythropoietin (EPO) that…

    Pain · Investigational · Subcutaneous injection, Intravenous

    No lawful pathway
  11. 083

    Afamelanotide (Scenesse)

    A synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH), [Nle4-D-Phe7]-alpha-MSH, with norleucine at position 4 and…

    Dermatology · FDA Approved · Subcutaneous implant

    FDA-approved
  12. 084

    Pentagastrin

    A synthetic pentapeptide containing the C-terminal tetrapeptide sequence of gastrin (Trp-Met-Asp-Phe-NH2) linked to beta-alanine. Pentagastrin stimulates…

    Diagnostic · FDA Approved · Subcutaneous injection, Intramuscular injection

    FDA-approved
  13. 085

    Icatibant (Firazyr)

    A synthetic decapeptide bradykinin B2 receptor antagonist containing five non-natural amino acids for enhanced stability and receptor selectivity. Icatibant…

    Immune · FDA Approved · Subcutaneous injection

    FDA-approved
  14. 086

    Palmitoylethanolamide (PEA)

    An endogenous fatty acid amide belonging to the N-acylethanolamine family, produced by cells in response to tissue damage and inflammation. In mouse models…

    Pain · In Clinical Trials · Oral

    No lawful pathway
  15. 087

    Orforglipron

    Orforglipron is a non-peptide, oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist developed as an alternative to injectable GLP-1 drugs. It…

    Metabolic · FDA Approved · Oral

    FDA-approved
  16. 088

    Mazdutide

    Mazdutide is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist given as a once-weekly subcutaneous peptide injection. By co-activating both…

    Metabolic · In Clinical Trials · Subcutaneous injection

    No lawful pathway
  17. 089

    Survodutide

    Survodutide is a dual agonist of the glucagon and glucagon-like peptide-1 (GLP-1) receptors, given as a once-weekly subcutaneous peptide injection. The…

    Metabolic · In Clinical Trials · Subcutaneous injection

    No lawful pathway
  18. 090

    CagriSema

    CagriSema is a once-weekly combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, both delivered as peptides by…

    Metabolic · In Clinical Trials · Subcutaneous injection

    No lawful pathway
  19. 091

    Amycretin

    Amycretin is a single-molecule (unimolecular) agonist of both the GLP-1 receptor and the amylin receptor, developed by Novo Nordisk for obesity in both oral…

    Metabolic · In Clinical Trials · Subcutaneous injection

    No lawful pathway
  20. 092

    Efinopegdutide

    Efinopegdutide (MK-6024) is a long-acting dual agonist of the GLP-1 and glucagon receptors given once weekly by subcutaneous injection. The compound combines…

    Metabolic · In Clinical Trials · Subcutaneous injection

    No lawful pathway
  21. 093

    Danuglipron

    Danuglipron (PF-06882961) is an oral, non-peptide small-molecule agonist of the GLP-1 receptor that was developed for type 2 diabetes and obesity. It mimics…

    Metabolic · Investigational · Oral

    No lawful pathway
  22. 094

    Ecnoglutide

    Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist peptide developed by Sciwind Biosciences for once-weekly subcutaneous use, with an oral tablet form…

    Metabolic · In Clinical Trials · Subcutaneous injection

    No lawful pathway
  23. 095

    Cotadutide

    Cotadutide (MEDI0382) is a dual agonist of the GLP-1 and glucagon receptors formulated as a peptide for once-daily subcutaneous injection. It was designed to…

    Metabolic · Investigational · Subcutaneous injection

    No lawful pathway
  24. 096

    Glepaglutide

    Glepaglutide is a long-acting GLP-2 receptor agonist peptide developed for the treatment of short bowel syndrome (SBS), designed as a ready-to-use injection.…

    Metabolic · In Clinical Trials · Subcutaneous injection

    No lawful pathway
  25. 097

    Apraglutide

    Apraglutide is a long-acting glucagon-like peptide-2 (GLP-2) receptor agonist given once weekly by subcutaneous injection, designed to promote intestinal…

    Metabolic · In Clinical Trials · Subcutaneous injection

    No lawful pathway
  26. 098

    Teduglutide (Gattex)

    Teduglutide is a recombinant analogue of human glucagon-like peptide-2 (GLP-2) comprising 33 amino acids with a single amino acid substitution that confers…

    Metabolic · FDA Approved · Subcutaneous injection

    FDA-approved
  27. 099

    Beinaglutide

    Beinaglutide is a recombinant human GLP-1 (rhGLP-1) used in China as a treatment for type 2 diabetes. Unlike long-acting GLP-1 analogues, it is short-acting…

    Metabolic · In Clinical Trials · Subcutaneous injection

    No lawful pathway
  28. 100

    Albiglutide (Tanzeum)

    Albiglutide is a GLP-1 receptor agonist made of modified human GLP-1 sequences fused to human albumin, giving it an elimination half-life of about 5 days that…

    Metabolic · FDA Approved · Subcutaneous injection

    FDA-approved
  29. 101

    Taspoglutide

    Taspoglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist derived from human GLP-1 with amino acid substitutions designed to resist…

    Metabolic · Investigational · Subcutaneous injection

    No lawful pathway
  30. 102

    Pemvidutide

    Pemvidutide (ALT-801) is a dual receptor agonist targeting the glucagon-like peptide-1 (GLP-1) and glucagon receptors, given once weekly by subcutaneous…

    Metabolic · In Clinical Trials · Subcutaneous injection

    No lawful pathway
  31. 103

    Cagrilintide

    Cagrilintide is a long-acting amylin analogue given once weekly by subcutaneous injection and developed for weight management. Amylin is a 37-amino-acid…

    Metabolic · In Clinical Trials · Subcutaneous injection

    No lawful pathway
  32. 104

    Enlicitide

    Enlicitide (enlicitide decanoate, formerly MK-0616) is an oral macrocyclic peptide that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9)…

    Metabolic · FDA Approved · Oral

    FDA-approved
  33. 105

    Capromorelin (Entyce)

    Capromorelin is a ghrelin receptor agonist (growth hormone secretagogue) that mimics ghrelin by binding the GHS-R1a receptor, which stimulates appetite and…

    Hormone · Investigational · Oral

    No lawful pathway
  34. 106

    Anamorelin (Adlumiz)

    Anamorelin is an orally active ghrelin receptor agonist that acts at the growth hormone secretagogue receptor (GHS-R1a) to stimulate appetite, food intake…

    Hormone · In Clinical Trials · Oral

    No lawful pathway
  35. 107

    Relamorelin

    Relamorelin (RM-131) is a synthetic pentapeptide ghrelin receptor agonist that activates the GHS-1a receptor with about sixfold greater potency than native…

    Hormone · Investigational · Subcutaneous injection

    No lawful pathway
  36. 108

    Mod GRF 1-29 (CJC-1295 no DAC)

    Modified GRF 1-29 is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions, the same…

    Hormone · Research Phase · Subcutaneous injection

    No lawful pathway

Index · all 264 peptides, A–Z

Important Medical Disclaimer

The information provided by the Peptide Association is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified, licensed healthcare provider before beginning any peptide therapy, supplement regimen, or making changes to an existing treatment plan.

Peptide therapies discussed on this site may not be FDA-approved for all listed indications. Individual results vary. The Peptide Association does not prescribe, diagnose, or treat any medical condition. Clinicians in our network are independently licensed practitioners; the Association checks each clinician’s NPI record but does not employ or directly supervise these clinicians.

© 2026 The Peptide Association. All rights reserved. Content on this site is protected under applicable intellectual property laws. The Peptide Association is not a medical practice.